

1 **Duration of Antiplatelet Therapy After Complex Percutaneous Coronary Intervention In**  
 2 **Patients at High Bleeding Risk: a MASTER DAPT trial sub-analysis**

3  
 4 Marco Valgimigli, M.D., Ph.D., Pieter C. Smits, M.D., Ph.D., Enrico Frigoli, M.D., Dario Bongiovanni,  
 5 M.D., Jan Tijssen, Ph.D., Thomas Hovasse, M.D., Al. Mafragi, M.D., W.T. Ruifrok, M.D., Dimitar  
 6 Karageorgiev, M.D., Adel Aminian, M.D., Stefano Garducci, M.D., Bela Merkely, M.D., Helen  
 7 Routledge, M.D., Kenji Ando, M.D., José Francisco Diaz Fernandez, M.D., Thomas Cuisset, M.D.,  
 8 Fazila Tun Nesa Malik, M.D., Majdi Halabi, M.D., Loic Belle, M.D., Jehangir Din, M.D., Farzin Beygui,  
 9 M.D., Atul Abhyankar, M.D., Krzysztof Reczuch, M.D., Giovanni Pedrazzini, M.D., Dik Heg, Ph.D.,  
 10 Pascal Vranckx, M.D., Ph.D., for the MASTER DAPT Investigators\*

11  
 12 From the Cardiocentro Institute, Ente Ospedaliero Cantonale, Università della Svizzera Italiana (USI),  
 13 CH- 6900 Lugano, Switzerland (M.V., D.B., G.P); CTU Bern, University of Bern, Bern, Switzerland  
 14 (E.F., D.H.); Amsterdam University Medical Center, the Netherlands (J.T.); Ramsay Générale de  
 15 Santé, ICPS, Hôpital Jacques Cartier, Massy, France (T.H.); Department of Cardiology, Zorgsaam  
 16 Hospital, Terneuzen, the Netherlands (A.M.); Treant Zorggroep, Emmen, the Netherlands, (W.T. R.);  
 17 BAL Sveta Karidad, Plovdiv, Bulgaria (D.K.); Department of Cardiology, Centre Hospitalier  
 18 Universitaire de Charleroi, Charleroi, Belgium (A.A.); Unita' Operativa Complessa di Cardiologia, ASST  
 19 Di Vimercate (MB), Vimercate, Italy (S.G.); Heart and Vascular Center, Semmelweis University,  
 20 Budapest, Hungary (B.M.); Worcestershire Royal Hospital, Worcester, UK (H.R.); Department of  
 21 Cardiology, Kokura Memorial Hospital, Kitakyushu, Japan (K.A.); Department of Cardiology, Hospital  
 22 Universitario Juan Ramón Jiménez, Huelva, Spain (J.F.D.F.); Assistance Publique - Hôpitaux de  
 23 Marseille, Centre Hospitalier Universitaire La Timone, Service de Cardiologie, Marseille, France (T.C.);  
 24 National Heart Foundation Hospital and Research Institute, Dhaka, Bangladesh (F.T.N.M.);  
 25 Department of Cardiology, Ziv Medical Center, Safed, Israel (M.H.); Cardiology Department, Hospital of  
 26 Annecy, Annecy, France (L.B.); Royal Bournemouth Hospital, East Bournemouth, UK (J.D.); Service

© The Author(s) 2022. Published by Oxford University Press on behalf of European Society of Cardiology. All rights reserved. For permissions, please e-mail: [journals.permissions@oup.com](mailto:journals.permissions@oup.com) This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ([https://academic.oup.com/journals/pages/open\\_access/funder\\_policies/chorus/standard\\_publication\\_model](https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)) 1

1 de Cardiologie, Centre Hospitalier Universitaire (CHU) de Caen Normandie, Caen, France;  
2 Électrophysiologie et imagerie des lésions d'ischémie-reperfusion myocardique, Normandie Univ,  
3 UNICAEN, Caen, France (F.B.); Department of Cardiology, Shree B. D. Mehta Mahavir Heart Institute,  
4 Surat, India (A.A.); Institute of Heart Diseases, Wrocław Medical University, Wrocław, Poland (K.R.);  
5 Department of Cardiology, Maastad Hospital, Rotterdam, the Netherlands (P.C.S.); Department of  
6 Cardiology and Critical Care Medicine, Hartcentrum Hasselt, Jessa Ziekenhuis Hasselt, faculty of  
7 medicine and life sciences University of Hasselt, Hasselt, Belgium (P.V.).

8

9 \*A complete list of the MASTER DAPT investigators is provided in the [Supplementary Appendix](#).

10 The MASTER DAPT trial is conducted with support from Terumo.

11

12 Corresponding author. Marco Valgimigli, Cardiocentro Institute, Ente Ospedaliero Cantonale,  
13 Università della Svizzera Italiana (USI), CH- 6900 Lugano, Switzerland.

14 [marco.valgimigli@cardiocentro.org](mailto:marco.valgimigli@cardiocentro.org)

15 Phone: +41 91 805 33 47

16 Fax: +41 91 805 3034

17

18

1 **Abstract:**

2 **Aims:** To assess the effects of 1- or  $\geq 3$ -month dual antiplatelet therapy (DAPT) in high bleeding risk  
3 (HBR) patients who received biodegradable-polymer sirolimus-eluting stents for complex percutaneous  
4 coronary intervention (PCI) and/or acute coronary syndrome (ACS).

5 **Methods and results:** In the MASTER DAPT trial, 3383 patients underwent noncomplex (abbreviated  
6 DAPT,  $n=1707$ ; standard DAPT,  $n=1676$ ) and 1196 complex (abbreviated DAPT,  $n=588$ ; standard DAPT,  
7  $n=608$ ) PCI. Co-primary outcomes at 335 days were net adverse clinical events (NACE; composite of all-  
8 cause death, myocardial infarction, stroke, and Bleeding Academic Research Consortium [BARC] 3 or 5  
9 bleeding events); major adverse cardiac or cerebral events (MACCE; all-cause death, myocardial  
10 infarction, and stroke); and type 2, 3, or 5 BARC bleeding.

11 NACE and MACCE did not differ with abbreviated versus standard DAPT among patients with complex  
12 (hazard ratio [HR]: 1.03, 95% confidence interval [CI]: 0.69–1.52, and HR: 1.24, 95% CI: 0.79–1.92,  
13 respectively) and noncomplex PCI (HR: 0.90, 95% CI: 0.71–1.15, and HR: 0.91, 95% CI: 0.69–1.21;  
14  $P_{\text{interaction}}=0.60$  and 0.26, respectively). BARC 2, 3 or 5 was reduced with abbreviated DAPT in patients  
15 with and without complex PCI (HR: 0.64; 95% CI: 0.42–0.98, and HR: 0.70; 95% CI: 0.55–0.89;  
16  $P_{\text{interaction}}=0.72$ ). Among the 2,816 patients with complex PCI and/or ACS, NACE and MACCE did not differ  
17 and BARC 2, 3 or 5 was lower with abbreviated DAPT.

18 **Conclusion:**

19 In HBR patients free from recurrent ischemic events at 1 month, DAPT discontinuation was associated  
20 with similar NACE and MACCE and lower bleeding rates compared with standard DAPT, regardless of  
21 PCI or patient complexity.

22 **Keywords:**

23 Percutaneous coronary intervention, high bleeding risk, dual antiplatelet therapy, complex intervention.

24 This trial is registered with ClinicalTrials.gov, number NCT03023020, and is closed to new participants,  
25 with follow-up completed.

26

**Key Question**

To assess the consistency of the treatment effects of 1- or ≥ 3-month dual antiplatelet therapy (DAPT) in high bleeding risk (HBR) patients with complex percutaneous coronary intervention (PCI) and/or acute coronary syndrome (ACS).

**Key Finding**

One-month DAPT after PCI with biodegradable-polymer sirolimus-eluting stent in HBR patients was associated with similar net adverse clinical events (NACE) and major adverse cardiac or cerebral events (MACCE) and lower bleeding rates compared with standard DAPT, regardless of PCI complexity and/or ACS.

**Take Home Message**

In HBR patients undergoing PCI without recurrent ischemic events in the first 30 days after coronary intervention, PCI complexity and/or ACS does not justify a DAPT regimen longer than one month.



Graphical Abstract

1  
2  
3

## 1 INTRODUCTION

2 Patients undergoing percutaneous coronary intervention (PCI) with severe coronary artery disease (CAD)  
3 and challenging lesion subsets require complex procedures and remain at increased risk of short- and  
4 long-term adverse ischemic events<sup>1-5</sup>.

5 A prior retrospective analysis of 6 randomized controlled trials, including 9,577 patients, showed that  
6 among 1,680 unselected complex PCI patients, the risk of major adverse cardiac events was lower with a  
7 12-month compared with a 3–6-month dual antiplatelet therapy (DAPT) regimen, with significant treatment  
8 duration by PCI complexity interaction testing<sup>2</sup>. A subsequent analysis which gathered individual patient  
9 data from 8 randomized controlled trials and 14,963 patients, suggested that the bleeding risk might be an  
10 additional treatment modifier, based on the observation that an ischemic benefit with prolonged treatment  
11 was observed only in patients not at high bleeding risk (HBR) who underwent complex PCI and/or were  
12 intervened upon with acute coronary syndrome (ACS) (complex patient group)<sup>1</sup>. No benefit in terms of  
13 ischemic endpoints was noted with prolonged DAPT in HBR patients, irrespective of PCI or patient  
14 complexity<sup>1</sup>. On the other hand, and regardless of PCI or patient complexity, extended DAPT duration  
15 remains associated with an increased risk of major bleeding<sup>1,2</sup>, especially among HBR patients<sup>1</sup>.

16 The aforementioned evidence informed the design of the MASTER DAPT (The Management of High  
17 Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated  
18 Versus Standard DAPT Regimen) trial, which randomised HBR patients to one- or at least 3-month DAPT,  
19 irrespective of PCI complexity and/or ACS at presentation<sup>6</sup>. The primary results showed that one month of  
20 DAPT was noninferior to treatment continuation for at least 2 additional months for the occurrence of net  
21 and major adverse clinical events and reduced major or clinically relevant nonmajor bleeding in the overall  
22 HBR population<sup>7</sup>. In this study, we conducted a prespecified analysis to assess the consistency of the  
23 treatment effects of one-month versus a more prolonged DAPT duration based on PCI and patient (i.e.  
24 complex PCI and/or ACS) complexity.

25

26

## 1 **METHODS**

### 2 **Study design**

3 The design and the primary endpoint results of the MASTER DAPT (ClinicalTrials.gov number,  
4 NCT03023020) investigator-initiated, randomized, open-label, noninferiority trial with sequential superiority  
5 testing in largely unselected patients at HBR following implantation of a biodegradable polymer-coated  
6 Ultimaster™ (Terumo Corporation, Tokyo, Japan) sirolimus-eluting stent, were reported previously<sup>6, 7</sup>.  
7 Ethics approval was obtained in each country and centre. All patients gave written informed consent. An  
8 independent data safety monitoring board regularly reviewed the conduct of the trial and the safety of the  
9 patients.

### 10 **Study patients**

11 Patients at high risk for bleeding who underwent treatment of all planned coronary artery stenoses with  
12 Ultimaster stent implantation for acute or chronic coronary syndromes were eligible if they remained  
13 uneventful until the time of randomization. Patients were considered at HBR if at least one of the following  
14 criteria applied: oral anticoagulant (OAC) therapy for at least 12 months, recent (<12 months) non-access  
15 site bleeding episode(s) that required medical attention, previous bleeding episode(s) that required  
16 hospitalization if the underlying cause had not been definitively treated, age  $\geq 75$  years, systemic  
17 conditions associated with an increased bleeding risk (e.g. haematological disorders or any known  
18 coagulation disorder associated with increased bleeding risk), documented anaemia (defined as repeated  
19 haemoglobin levels  $< 11$  g/dL or transfusion within 4 weeks before randomization), need for chronic  
20 treatment with steroids or non-steroidal anti-inflammatory drugs (NSAIDs), diagnosed malignancy (other  
21 than skin), stroke at any time or transient ischaemic attack in the previous 6 months, and PRECISE-DAPT  
22 score  $\geq 25$ <sup>6-8</sup>.

23 Exclusion criteria were minimal and limited to implantation of a non-study stent within the previous 6  
24 months or a bioresorbable scaffold at any time before the index procedure, or if they underwent treatment  
25 because of an in-stent restenosis or stent thrombosis.

26 Complex PCI was primarily defined as a procedure with at least one of the following angiographic  
27 characteristics: 3 vessels treated,  $\geq 3$  stents implanted,  $\geq 3$  lesions treated, bifurcation with 2 stents

1 implanted, total stent length >60 mm, or chronic total occlusion as target lesion<sup>1,2</sup>. An alternative and more  
2 comprehensive complex PCI definition which includes, in addition to all previous complex PCI criteria, also  
3 left main or graft intervention has also been used as sensitivity analysis<sup>9</sup>. Complex patients were defined  
4 as those fulfilling the primary complex PCI definition and/or with ACS, including ST-segment elevation or  
5 non-ST-segment elevation myocardial infarction or unstable angina.

## 6 **Randomization and follow-up**

7 Patients were centrally randomized (1:1 ratio) to an open-label abbreviated or non-abbreviated antiplatelet  
8 therapy regimen 30 to 44 days after the index procedure. Randomization was concealed using a web-  
9 based system; randomization sequences were computer generated, blocked, with randomly selected  
10 block sizes of 2, 4, or 6, and were stratified by site, history of acute myocardial infarction within the past 12  
11 months, and clinical indication for at least 12 months of OAC therapy. Follow-up visits occurred at 60±14  
12 and 150±14 days after randomization, preferably as on-site visits, and at 335±14 days after  
13 randomization, exclusively as an on-site visit. Three independent clinical research organisations (CERC,  
14 Massy, France; Cardialysis, Rotterdam, the Netherlands; and CVQuest, Tokyo, Japan) performed on-site  
15 and remote monitoring visits, verified the source documents, and collected source material for event  
16 adjudication. All events were adjudicated by an independent adjudication committee that was unaware of  
17 the treatment allocations. All data were stored at a central database (CTU, Bern, Switzerland).

## 18 **RANDOMIZED TREATMENT**

19 Patients randomly allocated to the abbreviated treatment group immediately discontinued DAPT and  
20 continued single antiplatelet therapy (SAPT) until study completion, except for those receiving OAC, who  
21 continued SAPT up to 6 months after the index procedure. Patients allocated to the standard treatment  
22 group continued DAPT for at least 5 additional months (6 months after the index procedure) or, for those  
23 receiving OAC, for at least 2 additional months (3 months after the index procedure) and continued  
24 thereafter on SAPT. Antiplatelet and anticoagulant treatments were dosed according to authorizations for  
25 use and locally approved regimens; detailed descriptions of the two treatment regimens are provided in  
26 the Supplementary Appendix.

## 27 **Outcomes**

1 The three ranked primary outcomes were net adverse clinical events (NACE) (a composite of death from  
2 any cause, myocardial infarction, stroke, or major bleeding), major adverse cardiac or cerebral events  
3 (MACCE) (a composite of death from any cause, myocardial infarction, or stroke), and major or clinically  
4 relevant non-major bleeding (composite of type 2, 3, or 5 Bleeding Academic Research Consortium  
5 [BARC] bleeding); cumulative incidences were assessed at 335 days.

6 The secondary outcomes included the individual components of the three co-primary outcomes;  
7 the composite of cardiovascular death, myocardial infarction, and stroke; the composite of cardiovascular  
8 death, myocardial infarction, definite or probable stent thrombosis, the composite of stroke and transient  
9 ischaemic attack; and all bleeding events, adjudicated according to the BARC classifications.

10 All outcomes were prespecified<sup>6,7</sup>. All analyses evaluated the occurrence of the adjudicated  
11 outcomes between randomization and 335 days.

## 12 **Statistical analysis**

13 The data were analysed according to the intention-to-treat principle. Outcomes were assessed separately  
14 for patients with or without complex PCI procedure, by calculating hazard ratios (HR) with 95% confidence  
15 intervals (CI).

16 For patients with a primary outcome, time-to-event was calculated as the difference between the date of  
17 occurrence of the outcome event and the date of randomization plus 1. For patients with incomplete  
18 clinical follow-up, time to censoring was defined as the difference between the dates of last known clinical  
19 status and randomization plus 1. Kaplan-Meier calculations included all (first) adjudicated outcome events  
20 that occurred between randomization and 335 days thereafter according to the randomized treatment  
21 assignment, irrespective of the DAPT regimen received at the time of the outcome event. HR and 95% CI  
22 were generated for primary and secondary outcomes with the use of Cox proportional hazards regression  
23 analysis with censoring at end of study and at the time of death. Competing risk of death (subdistribution  
24 HR with 95% CI) and the Aalen-Johansen cumulative incidences (with 95% CI) were computed for BARC  
25 bleeding endpoints following the Fine and Gray methodology<sup>10</sup>. Absolute risk differences are shown as  
26 percentage points. Numbers needed to treat for harm (NNTH) or benefit (NNTB) were calculated dividing  
27 1 by absolute risk difference for various endpoints between randomized groups.



1 *P*-values for testing homogeneity of the HR in subgroups of patients were derived in Cox  
2 proportional hazards models with the interaction term for treatment group (abbreviated vs standard) and  
3 complex PCI (yes vs no) tested using one degree of freedom. The 95% CI and *P*-values for interaction  
4 were not adjusted for multiplicity and should not be used to infer definitive treatment effects.  
5 Details on the statistical analysis have been published<sup>6, 7, 11</sup>.

## 6 RESULTS

7 From February 28, 2017 through December 5, 2019, 5204 patients (at 140 sites in 30 countries) were  
8 consented, of whom 1359 (26.1%) patients with and 3845 (73.9%) without complex PCI; a total of 1196  
9 (88%) patients with complex and 3383 (88%) without complex PCI were randomized (median 34 days  
10 post stenting, interquartile range: 32 to 39) to an abbreviated (n=2295 patients; complex PCI, n=588;  
11 noncomplex PCI, n=1707) or a standard (n=2284 patients complex PCI, n=608; noncomplex PCI, n=1676)  
12 DAPT regimen. Clinical and procedural characteristics of the patients who did not undergo randomization  
13 are shown in the supplementary appendix and were consistent across complex PCI strata (**Tables S1-2**).  
14 More patients in the non-complex PCI group withdrew after consent due to medical reasons whereas  
15 more patients in the complex PCI group died before randomization (**Table S3**). Complex PCI criteria  
16 distribution is shown in **Table S4**.

17 Patients with complex PCI were more likely to be older, have a history of prior myocardial infarction,  
18 arterial thromboembolism, chronic renal failure or non-ST-segment elevation acute coronary syndrome,  
19 but less likely to have prior bleeding or unstable angina, compared with the noncomplex PCI group  
20 (**Tables S5, S6**). Procedural characteristics were largely imbalanced between complex and noncomplex  
21 PCI patients (**Tables S6**). Antiplatelet therapies in complex and noncomplex PCI patients as stratified by  
22 study group are shown in **Figure 1** and **Table S7**. Type of antiplatelet therapy before and after  
23 randomization in patients with or without complex PCI in the abbreviated arm is shown in **Table S8**.  
24 Complex PCI patients incurred more myocardial infarctions compared with noncomplex PCI patients  
25 (3.6% vs. 2.0%; HR: 1.78, 95% CI:1.21–2.61, P=0.004), which was only marginally explained by a  
26 numerical difference in definite or probable stent thrombosis between groups (0.9% vs. 0.4%; HR: 2.17,  
27 95% CI:0.95–4.94, P=0.066, **Table S9**).

1 Baseline, angiographic and procedural characteristics, stratified by PCI complexity, were well balanced  
2 between the two antiplatelet regimens (**Tables 1 and S10**).

### 3 *Primary outcomes*

4 NACE and MACCE did not differ with abbreviated versus standard DAPT regimens among patients with  
5 complex (HR: 1.03, 95% CI: 0.69–1.52, P=0.90, risk difference 0.27 [-2.85 to 3.39] and HR: 1.24, 95% CI:  
6 0.79–1.92, P=0.349, risk difference 1.39 [-1.43 to 4.22], respectively) and non-complex PCI (HR: 0.90,  
7 95% CI: 0.71–1.15, P=0.418, risk difference -0.74 [-2.53 to 1.06], and HR: 0.91, 95% CI: 0.69–1.21, risk  
8 difference -0.53 [-2.11 to 1.06], P=0.520;  $P_{\text{interaction}}=0.60$  and 0.26, respectively). BARC 2, 3 or 5 bleeding  
9 was significantly and consistently reduced in patients with and without complex PCI (HR: 0.64; 95% CI:  
10 0.42-0.98, p=0.038, risk difference -3.11 [-6.13 to -0.10] and HR: 0.70; 95% CI: 0.55-0.89, risk difference -  
11 2.72 [-4.57 to -0.87], p=0.004;  $P_{\text{interaction}}=0.72$ ) (**Table 2 and Figures 1, 2**). The primary bleeding endpoint  
12 remained reduced with abbreviated DAPT in patients with or without complex PCI at competing risk of  
13 death analyses (**Table S11**). The results remained entirely consistent when an alternative and more  
14 comprehensive complex PCI definition was explored at post-hoc analysis (**Table S12**).

### 15 *Secondary outcomes*

16 There was no overall evidence of heterogeneity of the treatment effects in relation to PCI complexity and  
17 none of the secondary endpoints differed between abbreviated and standard DAPT regimens in complex  
18 or noncomplex PCI groups, with the only exceptions for BARC 1 and BARC 2 bleeding, which were lower  
19 (HR: 0.58; 95% CI: 0.40-0.83, p=0.003, HR: 0.67; 95% CI: 0.50-0.90, p=0.007, respectively) or trended  
20 lower (HR: 0.61; 95% CI: 0.34-1.07, p=0.08, HR: 0.63; 95% CI: 0.38-1.02, p=0.06, respectively) with  
21 abbreviated compared with standard DAPT in noncomplex and complex PCI groups, respectively (**Table 2**  
22 **and Figure 1**). The results remained entirely consistent when an alternative and more comprehensive  
23 complex PCI definition as explored in post-hoc analysis (**Table S12**).

### 24 *Complex PCI and/or acute coronary syndrome*

25 NACE and MACCE did not differ with abbreviated versus standard DAPT regimens among patients with  
26 complex PCI and/or ACS (n=2,816; HR: 0.94, 95% CI: 0.73–1.21, P=0.62 and HR: 1.00, 95% CI: 0.76–  
27 1.33, P=0.97, respectively) and noncomplex PCI without ACS (n=1743; HR: 0.92, 95% CI: 0.64–1.32,  
28 P=0.66 and HR: 0.91, 95% CI: 0.69–1.21, P=0.520;  $P_{\text{interaction}}=0.94$  and 0.83, respectively) (**Table 3**).

1 BARC 2, 3 or 5 bleeding was significantly and consistently reduced in patients with or without complex  
2 PCI and/or ACS (HR: 0.70; 95% CI: 0.53-0.93,  $p=0.013$  and HR: 0.66; 95% CI: 0.48-0.91,  $p=0.012$ ;  
3  $P_{\text{interaction}}=0.78$ ). The primary bleeding endpoint remained reduced with abbreviated DAPT in patients with  
4 or without complex PCI and/or ACS at competing risk analyses (**Table S13**). The results remained entirely  
5 consistent with abbreviated versus standard DAPT regimens among ACS patients who underwent  
6 complex PCI ( $n=571$ ) and ACS patients who underwent noncomplex PCI ( $n=1640$ , **Table 4 and Figure 3**).  
7 Risk/Benefit tradeoff of abbreviated DAPT regimen  
8 The NNTB for myocardial infarction and definite or probable stent thrombosis, calculated from between-  
9 group non-significant differences, were consistently higher than the NNTB for BARC 2, 3 or 5 and BARC 3  
10 or 5, calculated from between-group significant or non-significant differences, in all complex PCI, complex  
11 PCI and/or ACS and complex PCI ACS patients with abbreviated compared with standard treatment  
12 (**Figure 4**).

## 13 **DISCUSSION**

14 The main findings of the current analysis from the international, multicenter, randomized MASTER DAPT  
15 trial, in which we examined the efficacy and safety of a one month vs. standard DAPT regimen in HBR  
16 patients after PCI, in relation to procedural or patient complexities, can be summarized as follows: (i)  
17 complex PCI or complex PCI and/or ACS at presentation did not affect the comparative efficacy and  
18 safety of an abbreviated vs. a more prolonged DAPT regimen in HBR patients. This observation is  
19 supported by negative interaction testing for the three ranked primary or major secondary endpoints; (ii)  
20 an abbreviated DAPT regimen was not associated with significantly higher risk of composite or individual  
21 ischemic events compared with standard DAPT among HBR patients with complex PCI or complex PCI  
22 and/or ACS at presentation; and (iii) an abbreviated DAPT regimen resulted in significantly lower major or  
23 clinically relevant nonmajor bleeding complications compared with a non-abbreviated DAPT regimen,  
24 which was consistent across complex PCI and complex PCI and/or ACS strata (Graphical abstract).  
25 MASTER DAPT, by design, enrolled HBR patients who underwent PCI of all intended de-novo lesions  
26 with biodegradable polymer-coated sirolimus-eluting stent(s), without restrictions based on number, type  
27 or location of the treated stenosis or clinical presentation<sup>6</sup>. This drove a large proportion of study patients  
28 fulfilling complex PCI criteria ( $N=1,196$  or 26%) and/or presented with ACS ( $N=2,211$  or 48.3%) or

1 presented both (N=571 or 12.5%) characteristics. To the best of our knowledge, the current analysis  
2 represents the largest study investigating 1- vs.  $\geq$  3-month DAPT after complex PCI in HBR patients.  
3 The analysis of consented versus included patients showed no discernable bias from PCI to 1-month  
4 randomization in relation to the presence or absence of complex PCI criteria; an identical proportion of  
5 patients (88%) with or without complex PCI entered the trial after being consented. Notably, 30-day  
6 mortality was higher in patients with one or more complex PCI criteria compared with the noncomplex PCI  
7 group, whereas from randomization to 335 days, complex PCI patients incurred more myocardial  
8 infarctions than noncomplex PCI patients, largely due to non-stent related occurrences. In the complex  
9 PCI group, definite or definite or probable stent thrombosis explained only 19% and 24% of the overall  
10 myocardial infarction cases, respectively. The corresponding figures in the noncomplex PCI group were  
11 15% and 19%, respectively. These findings indicate that, even in the context of complex PCI patients with  
12 or without ACS, undergoing a relatively short (6 months) or very short (1 month) DAPT regimen, the  
13 majority of myocardial infarctions derive from non-stented coronary segments<sup>12</sup>. Bleeding risk was not  
14 higher in complex compared with noncomplex PCI patients, which is also a consistent finding with  
15 previous studies<sup>13-15</sup>. Therefore, the consistency of the treatment effects of an abbreviated compared with  
16 a more prolonged DAPT regimen across the spectrum of PCI complexities remains critical to assess.  
17 More specifically, whether an abbreviated course of treatment mitigates bleeding without increasing  
18 ischemic risks in selected patients who underwent complex PCI.  
19 NACE or MACCE did not differ with abbreviated compared with standard DAPT in patients with or without  
20 complex PCI criteria with no signal of treatment-by-subgroup interaction. BARC 2, 3 or 5 bleeding was  
21 significantly and consistently reduced in patients with and without complex PCI. These findings suggest  
22 that PCI complexity does not justify *per se* a more prolonged course of DAPT, in excess of one month, in  
23 HBR patients who did not encounter recurrent ischemic events in the first 30 days after intervention. Our  
24 findings remained entirely consistent when the intersection between complex PCI and ACS at  
25 presentation (complex patients) was further investigated, therefore replicating prospectively, with an even  
26 shorted DAPT regimen, the previously published retrospective observations arising from a combined  
27 dataset of 8 trials which investigated 3 to 6 months versus DAPT versus 12 months or more of treatment  
28 duration<sup>1</sup>. Based on these prior findings, the control group of the present trial set DAPT duration at a

1 minimum of 3 months, with a median duration of 193 days (interquartile range, 102 to 366)<sup>6</sup>. The results of  
2 this analysis support the use of a further shortened DAPT duration (median 34 days; interquartile range,  
3 31 to 39) in HBR patients with or without complex PCI and irrespective of concomitant ACS. Our study  
4 was powered for assessing the non-inferiority of NACE and MACCE in the overall study population based  
5 on absolute risk differences expected to represent 30% of the corresponding event rates. No non-  
6 inferiority claim is obviously possible when interpreting subgroup-analyses, to which this study is by  
7 definition underpowered. Therefore, similar to all subgroup analyses, our study is hypothesis-generating  
8 with respect to the risks and benefits of an abbreviated compared with a standard DAPT regimen in  
9 patients who underwent complex PCI and/or with ACS. Our results are consistent with prior studies which  
10 assessed the consistency of the treatment effects of a shortened DAPT regimen of either 1<sup>4</sup> or 3<sup>9</sup>  
11 month(s), followed by ticagrelor monotherapy compared with 12-month DAPT in patients who were not  
12 selected based on HBR criteria and underwent complex PCI<sup>16</sup>.

13 When the secondary endpoints were separately appraised, the results observed in the over trial  
14 population were consistently replicated in patients with or without complex PCI, suggesting no significant  
15 excess of myocardial infarction, stent thrombosis or stroke with an abbreviated DAPT regimen, nor a  
16 significant difference of major bleeding. As observed in the overall trial population, there were numerical  
17 imbalances of myocardial infarction in disfavor, and of major bleeding in favor, of the abbreviated DAPT  
18 group in both complex and noncomplex PCI patients. The rate of definite or probable stent thrombosis  
19 was numerical lower with abbreviated compared with standard DAPT in the complex PCI group, which  
20 therefore did not explain the insignificant small excess of myocardial infarction observed with abbreviated  
21 DAPT in this patient subgroup. In the complex PCI patients, ticagrelor, rather than aspirin monotherapy,  
22 was more frequently selected after DAPT discontinuation in the abbreviated arm compared with  
23 noncomplex PCI patients. Ticagrelor monotherapy was shown more effective for myocardial infarction and  
24 stent thrombosis prevention compared with aspirin monotherapy<sup>17,18</sup>. However, in both complex and  
25 noncomplex PCI patients, clopidogrel remained the most frequently used antiplatelet therapy after DAPT  
26 in the abbreviated arm.

27 In the noncomplex PCI group, there was a small excess of stent thrombosis with abbreviated compared  
28 with standard DAPT, which explained 27% and 10% of the overall myocardial infarction events in the

1 abbreviated and standard groups, respectively. Our study was clearly underpowered for relatively rarer  
2 endpoints such as myocardial infarction or major bleeding and even more for stent thrombosis. As a  
3 result, despite nonsignificant, these observations may indicate the existence of a small risk of coronary  
4 ischemic events and a small benefit in terms of major bleeding with abbreviated DAPT, in both patients  
5 with or without complex PCI. The appraisal of the tradeoff between possible risks and possible benefit is  
6 essential as they have been shown to exert similar prognostic implications for mortality<sup>19</sup>.

7 The computation of NNTB for myocardial infarction or stent thrombosis and NNTB for major or major and  
8 clinically relevant minor bleeding showed that the former were lower than the latter in complex PCI,  
9 complex PCI and/or ACS as well as complex PCI and ACS. Therefore, even assuming the existence of a  
10 tradeoff between risks and benefits in HBR patients in relation to DAPT duration, our analysis support the  
11 hypothesis that 1-month DAPT remains the preferable treatment option in HBR patients who underwent  
12 complex PCI and did not experience ischemic recurrences in the first 1 month after treatment.

13 The present results need to be interpreted in light of the several imitations.

14 The absence of a universally accepted definition for complex PCI is notable. We used the criteria  
15 proposed by Giustino et al. because this approach integrated, by consensus, features of procedural  
16 complexity which were associated with higher risks in prior studies<sup>2</sup>, have been adopted since then by  
17 multiple investigators<sup>1, 4, 13-15</sup> and this definition was used to generate the hypothesis, tested in the  
18 MASTER DAPT trial, that presence of HBR is a treatment modifier for DAPT duration, irrespective of PCI  
19 or patient complexity. However, results remained entirely consistent when an alternative and more  
20 comprehensive complex PCI definition was implemented, suggesting robust findings. In the overall trial, as  
21 well as in the current sub-analysis, an abbreviated DAPT regimen was associated with lower BARC 2 but  
22 not BARC 3 or 5 bleeding events. Randomization was not stratified based on PCI complexity. However,  
23 we stratified based on history of acute myocardial infarction within the past 12 months, which almost  
24 exclusively comprised patients with ACS at presentation, as stenting within 6 months prior to  
25 randomization was an exclusion criterion. Our trial included HBR patients who underwent biodegradable-  
26 polymer sirolimus-eluting stent implantation; consequently, our results may not extend to non-HBR  
27 patients or who receive other stent types. Patients with in-stent restenosis or stent thrombosis were  
28 ineligible. The type of monotherapy after discontinuing dual antiplatelet therapy was at discretion of the

1 treating physicians and our results should be interpreted taking into account that ticagrelor was more and  
2 aspirin was less frequently preferred as monotherapy options in complex compared with noncomplex PCI  
3 groups in the abbreviated arm. The type of monotherapy after DAPT discontinuation in the abbreviated  
4 arm may have influenced the treatment effects and its role cannot be easily addressed in the current  
5 analysis due to the large number of factors that may have influenced the choice.

6 In conclusion, in HBR patients who underwent complex or noncomplex PCI with biodegradable-polymer  
7 sirolimus-eluting stent implantation and did not encounter early recurrent ischemic events, the  
8 discontinuation of DAPT a median of 34 days after PCI, compared with continuation of treatment for a  
9 median duration of 193 days, was consistently associated with similar rates of NACE and MACCE and a  
10 lower rate of major or clinically relevant nonmajor bleeding.

### 11 **Disclosure**

12 Marco Valgimigli received an institutional grant from Terumo and consulting fees from Astra  
13 Zeneca, Terumo, Alvimedica/CID, Abbott Vascular, Daiichi Sankyo, Bayer, CoreFLOW, DORSIA  
14 Pharmaceuticals LTD, Vifor, Bristol Myers Squibb SA, Biotronik, Boston scientific, Medtronic,  
15 Vesalio, Novartis, Chiesi, PhaseBio, ECRI. Pieter C. Smits received institutional grants from  
16 Microport, SMT, Daichy Sankyo and Abbott Vascular; consulting fees from Cavis and Abbott  
17 Vascular; honoraria from Abiomed, Terumo and Abbott Vascular; participated on advisory board  
18 of Terumo, Abbott Vascular and SMI. Bela Merkely received grants from Medtronic and Boston  
19 Scientific; Speaker fee from Biotronik, Abbott, Astra Zeneca, Boehringer Ingelheim and Novartis.  
20 Thomas Cuisset received consulting fees from Medtronic, Abbott vascular, Terumo and Boston  
21 Scientific; honoraria from Medtronic, Abbott vascular, Terumo and Boston Scientific. Fazila Tun  
22 Nesa Malik received consulting fees from Terumo. Krzysztof Reczuch received honoraria from  
23 Boston Scientific, Terumo and Astra Zeneca. Pascal Vranckx received consulting fees from  
24 Daiichi Sankyo, Novartis, CSL Behring and Bayer AG; honoraria from Daiichi Sankyo and  
25 Servier; participated on advisory board for Daiichi Sankyo. All other authors declared no conflict  
26 of interest.

### 27 **ROLE OF THE FUNDING SOURCE**

28 The study was sponsored by the European Cardiovascular Research Institute (ECRI), a non-profit  
29 organisation, and received grant support from Terumo. The sponsor and funder had no role in the study  
30 design, data collection, data monitoring, analysis, interpretation, or writing of the report.

31  
32

## 1 REFERENCES

- 2 1. Costa F, Van Klaveren D, Feres F, James S, Raber L, Pilgrim T, *et al.* Dual Antiplatelet Therapy  
3 Duration Based on Ischemic and Bleeding Risks After Coronary Stenting. *J Am Coll Cardiol*  
4 2019;**73**(7):741-754.
- 5 2. Giustino G, Chieffo A, Palmerini T, Valgimigli M, Feres F, Abizaid A, *et al.* Efficacy and Safety of  
6 Dual Antiplatelet Therapy After Complex PCI. *J Am Coll Cardiol* 2016;**68**(17):1851-1864.
- 7 3. Valgimigli M, Landi A. Ischaemic and bleeding risk in patients with acute coronary syndrome  
8 undergoing complex percutaneous coronary intervention: is it time to REACT? *Eur Heart J Acute*  
9 *Cardiovasc Care* 2021;**10**(10):1125-1128.
- 10 4. Serruys PW, Takahashi K, Chichareon P, Kogame N, Tomaniak M, Modolo R, *et al.* Impact of long-  
11 term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent  
12 complex percutaneous coronary intervention: insights from the Global Leaders trial. *Eur Heart J*  
13 2019;**40**(31):2595-2604.
- 14 5. Jeppsson A, Petricevic M, Kolh P, Valgimigli M. 2017 European Society of Cardiology (ESC)  
15 focused update on dual antiplatelet therapy in collaboration with the European Association for Cardio-  
16 Thoracic Surgery (EACTS). *Eur J Cardiothorac Surg* 2018;**53**(1):3-4.
- 17 6. Frigoli E, Smits P, Vranckx P, Ozaki Y, Tijssen J, Juni P, *et al.* Design and rationale of the  
18 Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With  
19 an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study. *Am Heart J* 2019;**209**:97-105.
- 20 7. Valgimigli M, Frigoli E, Heg D, Tijssen J, Juni P, Vranckx P, *et al.*; MASTER DAPT Investigators. Dual  
21 Antiplatelet Therapy after PCI in Patients at High Bleeding Risk. *N Engl J Med* 2021;**385**(18):1643-1655.
- 22 8. Costa F, van Klaveren D, James S, Heg D, Raber L, Feres F, *et al.*; PRECISE-DAPT Study  
23 Investigators. Derivation and validation of the predicting bleeding complications in patients undergoing  
24 stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of  
25 individual-patient datasets from clinical trials. *Lancet* 2017;**389**(10073):1025-1034.
- 26 9. Dangas G, Baber U, Sharma S, Giustino G, Mehta S, Cohen DJ, *et al.* Ticagrelor With or Without  
27 Aspirin After Complex PCI. *J Am Coll Cardiol* 2020;**75**(19):2414-2424.
- 28 10. Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk. *J Am*  
29 *Stat Assoc* 1999;**94**(446):496-509.
- 30 11. Smits PC, Frigoli E, Tijssen J, Juni P, Vranckx P, Ozaki Y, *et al.*; MASTER DAPT Investigators  
31 Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant



- 1 Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial. *Circulation*  
2 2021;**144**(15):1196-1211.
- 3 12. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, *et al.*; DAPT Study  
4 Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. *N Engl J Med*  
5 2014;**371**(23):2155-66.
- 6 13. Roh JW, Hahn JY, Oh JH, Chun WJ, Park YH, Jang WJ, *et al.* P2Y12 inhibitor monotherapy in  
7 complex percutaneous coronary intervention: A post-hoc analysis of SMART-CHOICE randomized clinical  
8 trial. *Cardiol J* 2021;**28**(6):855-863.
- 9 14. Coughlan JJ, Aytakin A, Ndrepepa G, Schupke S, Bernlochner I, Mayer K, *et al.* Twelve-month  
10 clinical outcomes in patients with acute coronary syndrome undergoing complex percutaneous coronary  
11 intervention: insights from the ISAR-REACT 5 trial. *Eur Heart J Acute Cardiovasc Care* 2021;**10**(10):1117-  
12 1124.
- 13 15. Yamamoto K, Watanabe H, Morimoto T, Domei T, Ohya M, Ogita M, *et al.* Very Short Dual  
14 Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients Who Underwent Complex  
15 Percutaneous Coronary Intervention: Insight From the STOPDAPT-2 Trial. *Circ Cardiovasc Interv*  
16 2021;**14**(5):e010384.
- 17 16. Valgimigli M, Gagnano F, Branca M, Franzone A, Baber U, Jang Y, *et al.* P2Y12 inhibitor  
18 monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-  
19 analysis of randomised controlled trials. *BMJ* 2021;**373**:n1332.
- 20 17. Valgimigli M, Mehran R, Franzone A, da Costa BR, Baber U, Piccolo R, *et al.* Ticagrelor  
21 Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis.  
22 *JACC Cardiovasc Interv* 2021;**14**(4):444-456.
- 23 18. Franzone A, McFadden E, Leonardi S, Piccolo R, Vranckx P, Serruys PW, *et al.*; GLASSY  
24 Investigators. Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting  
25 Coronary Stenting. *J Am Coll Cardiol* 2019;**74**(18):2223-2234.
- 26 19. Valgimigli M, Costa F, Likhnygina Y, Clare RM, Wallentin L, Moliterno DJ, *et al.* Trade-off of  
27 myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the  
28 Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER)  
29 randomized trial. *Eur Heart J* 2017;**38**(11):804-810.

30

1 **Legends**

2 **Figure 1. Antiplatelet regimens in complex (A) and noncomplex (B) PCI patients.**

3 Dark blue denotes dual antiplatelet therapy, light blue denotes single antiplatelet therapy (see  
4 Table S7 for type therefore and Table S8 for cross-overs), red denotes no antiplatelet therapy,  
5 black denotes deceased patients, white denotes no information.

6 DAPT, dual antiplatelet therapy; OAC, oral anticoagulation.

7 **Figure 2. Clinical endpoints stratified by complexity of percutaneous coronary**  
8 **intervention**

9 CI, confidence interval; DAPT, dual antiplatelet therapy; PCI, percutaneous coronary  
10 intervention; BARC, bleeding academic research consortium

11 **Figure 3. Kaplan-Meier curve for major or clinically relevant nonmajor bleeding stratified**  
12 **by complexity of percutaneous coronary intervention**

13 CI, confidence interval; DAPT, dual antiplatelet therapy; HR, hazard ratio.

14 **Figure 4. Clinical endpoints in acute coronary syndrome patients stratified by complexity**  
15 **of percutaneous coronary intervention**

16 CI, confidence interval; DAPT, dual antiplatelet therapy; PCI, percutaneous coronary  
17 intervention; BARC, Bleeding Academic Research Consortium

18  
19 **Graphical Abstract.**

20 One-month DAPT after PCI with biodegradable-polymer sirolimus-eluting stent in high bleeding  
21 risk patients was associated with similar NACE and MACCE and lower bleeding rates compared  
22 with standard DAPT, regardless of PCI complexity and/or ACS.

23

1 **Table 1. Baseline characteristics**

	Abbreviated DAPT		Standard DAPT		Complex	Noncomplex
	Complex PCI	Noncomplex PCI	Complex PCI	Noncomplex PCI	p-value	p-value
	N = 588	N = 1707	N = 608	N = 1676		
Age, years (mean ± SD)	n = 588, 76.51 ± 8.17	n = 1707, 75.98 ± 8.88	n = 608, 76.78 ± 8.30	n = 1676, 75.66 ± 8.92	0.570	0.298
Male sex (n [%])	n = 588, 419 (71.3%)	n = 1707, 1171 (68.6%)	n = 608, 428 (70.4%)	n = 1676, 1153 (68.8%)	0.751	0.911
Body mass index, kg/m <sup>2</sup> (mean ± SD)	n = 588, 27.56 ± 4.61	n = 1707, 27.15 ± 4.70	n = 608, 27.58 ± 4.62	n = 1676, 27.39 ± 4.79	0.943	0.136
Family history of coronary artery disease (n [%])	n = 588, 162 (27.6%)	n = 1707, 394 (23.1%)	n = 608, 148 (24.3%)	n = 1676, 405 (24.2%)	0.210	0.466
Known Arterial hypertension (n [%])	n = 588, 473 (80.4%)	n = 1707, 1293 (75.7%)	n = 608, 468 (77.0%)	n = 1676, 1319 (78.7%)	0.158	0.045
Uncontrolled hypertension (n [%])	n = 588, 23 (3.9%)	n = 1707, 96 (5.6%)	n = 608, 35 (5.8%)	n = 1676, 82 (4.9%)	0.141	0.356
Known Diabetes mellitus (n [%])	n = 588, 202 (34.4%)	n = 1707, 552 (32.3%)	n = 608, 203 (33.4%)	n = 1676, 581 (34.7%)	0.760	0.155
Known Hyperlipidemia (n [%])	n = 588, 420 (71.4%)	n = 1707, 1122 (65.7%)	n = 608, 403 (66.3%)	n = 1676, 1152 (68.7%)	0.061	0.067
Smoker (n [%])	n = 588	n = 1702	n = 607	n = 1669	0.071	0.130
no - never smoked	287 (48.8%)	899 (52.8%)	336 (55.4%)	902 (54.0%)	0.024	0.490
yes - previous smoker	254 (43.2%)	620 (36.4%)	232 (38.2%)	622 (37.3%)	0.088	0.617
yes - current smoker	47 (8.0%)	183 (10.8%)	39 (6.4%)	145 (8.7%)	0.315	0.048
Known Peripheral/Vascular disease* (n [%])	n = 588, 75 (12.8%)	n = 1707, 168 (9.8%)	n = 608, 62 (10.2%)	n = 1676, 180 (10.7%)	0.174	0.396
Known Carotid artery disease* (n [%])	n = 588, 32 (5.4%)	n = 1707, 88 (5.2%)	n = 608, 38 (6.3%)	n = 1676, 106 (6.3%)	0.623	0.160
History of heart failure (n [%])	n = 588, 116 (19.7%)	n = 1707, 313 (18.3%)	n = 608, 119 (19.6%)	n = 1676, 319 (19.0%)	1.000	0.628
Left ventricular ejection fraction, % (mean ± SD)	n = 559, 53.05 ± 11.29	n = 1610, 53.63 ± 11.49	n = 581, 52.27 ± 11.65	n = 1547, 53.22 ± 11.81	0.250	0.324
Prior myocardial infarction (n [%])	n = 588, 124 (21.1%)	n = 1707, 310 (18.2%)	n = 608, 145 (23.8%)	n = 1676, 285 (17.0%)	0.268	0.391
Prior PCI (n [%])	n = 588, 159 (27.0%)	n = 1707, 435 (25.5%)	n = 608, 153 (25.2%)	n = 1676, 441 (26.3%)	0.469	0.583
Prior cerebrovascular event reported (n [%])	n = 588, 79 (13.4%)	n = 1707, 189 (11.1%)	n = 608, 76 (12.5%)	n = 1676, 226 (13.5%)	0.667	0.036
Stroke (n [%])	n = 588, 58 (9.9%)	n = 1707, 135 (7.9%)	n = 608, 56 (9.2%)	n = 1676, 161 (9.6%)	0.768	0.088
TIA (n [%])	n = 588, 27 (4.6%)	n = 1707, 59 (3.5%)	n = 608, 18 (3.0%)	n = 1676, 66 (3.9%)	0.171	0.467

Undetermined Cerebrovascular event (n [%])	n = 588, 3 (0.5%)	n = 1707, 8 (0.5%)	n = 608, 5 (0.8%)	n = 1676, 13 (0.8%)	0.726	0.281
Known History of Arterial thromboembolism (n [%])	n = 588, 14 (2.4%)	n = 1707, 17 (1.0%)	n = 608, 10 (1.6%)	n = 1676, 14 (0.8%)	0.413	0.719
Known History of Venous thromboembolism (n [%])	n = 588, 41 (7.0%)	n = 1707, 83 (4.9%)	n = 608, 34 (5.6%)	n = 1676, 81 (4.8%)	0.342	1.000
Prior CABG (n [%])	n = 588, 46 (7.8%)	n = 1707, 124 (7.3%)	n = 608, 46 (7.6%)	n = 1676, 125 (7.5%)	0.914	0.844
Prior Prosthetic mechanical heart valve (n [%])	n = 588, 8 (1.4%)	n = 1707, 35 (2.1%)	n = 608, 11 (1.8%)	n = 1676, 47 (2.8%)	0.646	0.180
Known Aortic Valve Stenosis (n [%])	n = 518, 22 (4.2%)	n = 1551, 69 (4.4%)	n = 550, 31 (5.6%)	n = 1501, 73 (4.9%)	0.326	0.607
Prior bleeding before/after qualifying PCI (n [%])	n = 588, 39 (6.6%)	n = 1707, 145 (8.5%)	n = 608, 34 (5.6%)	n = 1676, 141 (8.4%)	0.471	0.951
Known Chronic pulmonary disease (n [%])	n = 588, 72 (12.2%)	n = 1707, 183 (10.7%)	n = 608, 72 (11.8%)	n = 1676, 211 (12.6%)	0.859	0.097
Known Chronic Renal Failure (n [%])	n = 588, 131 (22.3%)	n = 1707, 287 (16.8%)	n = 608, 122 (20.1%)	n = 1676, 336 (20.0%)	0.358	0.017
Known Liver disease (n [%])	n = 588, 8 (1.4%)	n = 1707, 21 (1.2%)	n = 608, 8 (1.3%)	n = 1676, 24 (1.4%)	1.000	0.654
Atrial fibrillation (n [%])	n = 588, 180 (30.6%)	n = 1707, 590 (34.6%)	n = 608, 181 (29.8%)	n = 1676, 539 (32.2%)	0.753	0.145
Known History of cancer (n [%])	n = 588, 98 (16.7%)	n = 1707, 250 (14.6%)	n = 608, 98 (16.1%)	n = 1676, 253 (15.1%)	0.815	0.735
Known Active cancer (n [%])	n = 588, 41 (7.0%)	n = 1707, 69 (4.0%)	n = 608, 33 (5.4%)	n = 1676, 93 (5.5%)	0.282	0.044
Known Haematological or Coagulation Disorders (n [%])	n = 588, 86 (14.6%)	n = 1707, 204 (12.0%)	n = 608, 79 (13.0%)	n = 1676, 209 (12.5%)	0.451	0.674
Chronic treatment with steroids or NSAIDs (n [%])	n = 588, 60 (10.2%)	n = 1707, 142 (8.3%)	n = 608, 68 (11.2%)	n = 1676, 171 (10.2%)	0.640	0.066
Prior VKA (n [%])	n = 588, 67 (11.4%)	n = 1707, 260 (15.2%)	n = 608, 64 (10.5%)	n = 1676, 235 (14.0%)	0.644	0.331
Need for current treatment with OAC (n [%])	n = 588, 200 (34.0%)	n = 1707, 649 (38.0%)	n = 608, 215 (35.4%)	n = 1676, 605 (36.1%)	0.628	0.255
Clinical indication for 12 months OAC (n [%])	n = 588, 200 (34.0%)	n = 1707, 648 (38.0%)	n = 608, 214 (35.2%)	n = 1676, 604 (36.0%)	0.671	0.255
OAC treatment at randomization (n [%])	n = 200, 199 (99.5%)	n = 648, 643 (99.2%)	n = 214, 213 (99.5%)	n = 604, 601 (99.5%)	1.000	0.727
PRECISE-DAPT score <sup>††</sup> (mean ± SD)	n = 588, 27.13 ± 11.54	n = 1707, 26.70 ± 10.69	n = 608, 26.91 ± 10.59	n = 1676, 26.64 ± 11.22	0.732	0.865
Prior bleeding (n [%])	n = 588, 37 (6.3%)	n = 1707, 128 (7.5%)	n = 608, 29 (4.8%)	n = 1676, 126 (7.5%)	0.257	1.000
Hemoglobin, g/L (mean ± SD)	n = 588, 13.08 ± 1.80	n = 1707, 13.29 ± 1.77	n = 608, 13.07 ± 1.81	n = 1676, 13.24 ± 1.79	0.951	0.439
White blood cell count <sup>††</sup> , 10 <sup>9</sup> /L (mean ± SD)	n = 588, 8.73 ± 21.50	n = 1707, 8.13 ± 4.09	n = 607, 8.05 ± 4.07	n = 1676, 8.06 ± 3.12	0.440	0.542
Creatinine clearance MDRD, ml/min/1.73 m <sup>2</sup> (mean ± SD)	n = 588, 69.77 ± 24.20	n = 1707, 71.05 ± 23.91	n = 608, 69.68 ± 24.33	n = 1676, 71.48 ± 24.00	0.947	0.595

1 Reported are means with standard deviations (±SD), counts (% of patients).

2 TIA: transient ischemic attack; PCI: percutaneous coronary intervention; CABG: coronary artery bypass grafting; NSAID: non steroidal anti inflammatory drug; OAC: oral anticoagulation (vitamin K-

3 antagonist VKA or NOAC).

4 <sup>††</sup>calculated at screening visit. n=1 PRECISE Score calculated without risk due to white blood cell count.

5

1 **Table 2. Clinical endpoints at 11 months post-randomization**

	Complex PCI					Noncomplex PCI					interaction p-value
	Abbreviated DAPT	Standard DAPT	Hazard ratio (95% CI)	p-value	Absolute risk difference [95% CI]	Abbreviated DAPT	Standard DAPT	Hazard ratio (95% CI)	p-value	Absolute risk difference [95% CI]	
	N = 588	N = 608				N = 1707	N = 1676				
Net Adverse Clinical Events (NACE)	49 (8.35)	49 (8.08)	1.03 (0.69-1.52)	0.900	0.27 [-2.85 to 3.39]	123 (7.24)	133 (7.98)	0.90 (0.71-1.15)	0.418	-0.74 [-2.53 to 1.06]	0.595
Major Adverse Cardiac or Cerebral events (MACCE)	43 (7.33)	36 (5.94)	1.24 (0.79-1.92)	0.349	1.39 [-1.43 to 4.22]	95 (5.59)	102 (6.12)	0.91 (0.69-1.21)	0.520	-0.53 [-2.11 to 1.06]	0.256
Major or Clinically Relevant Nonmajor Bleeding (MCB)	35 (6.03)	55 (9.15)	0.64 (0.42-0.98)	0.038	-3.11 [-6.13 to -0.10]	113 (6.71)	156 (9.44)	0.70 (0.55-0.89)	0.004	-2.72 [-4.57 to -0.87]	0.723
Death	19 (3.24)	18 (2.97)	1.09 (0.57-2.07)	0.797	0.27 [-1.70 to 2.24]	56 (3.30)	63 (3.78)	0.87 (0.61-1.25)	0.449	-0.48 [-1.73 to 0.77]	0.553
Cardiovascular death	9 (1.55)	10 (1.66)	0.93 (0.38-2.28)	0.870	-0.11 [-1.54 to 1.32]	28 (1.66)	34 (2.06)	0.81 (0.49-1.33)	0.399	-0.40 [-1.31 to 0.52]	0.790
Non-cardiovascular death	6 (1.03)	7 (1.17)	0.88 (0.30-2.63)	0.825	-0.13 [-1.32 to 1.05]	23 (1.37)	21 (1.28)	1.07 (0.59-1.94)	0.818	0.09 [-0.68 to 0.87]	0.759
Undetermined death	4 (0.69)	1 (0.17)	4.12 (0.46-36.86)	0.205	0.52 [-0.23 to 1.28]	5 (0.30)	8 (0.49)	0.61 (0.20-1.87)	0.390	-0.19 [-0.61 to 0.24]	0.128
Cardiovascular or Undetermined death	13 (2.23)	11 (1.83)	1.22 (0.55-2.72)	0.631	0.41 [-1.20 to 2.01]	33 (1.95)	42 (2.53)	0.77 (0.49-1.21)	0.260	-0.58 [-1.59 to 0.42]	0.329
Cerebrovascular Accident	4 (0.70)	5 (0.84)	0.82 (0.22-3.07)	0.773	-0.14 [-1.14 to 0.86]	13 (0.78)	27 (1.64)	0.47 (0.24-0.91)	0.025	-0.87 [-1.61 to -0.12]	0.452
Stroke	3 (0.52)	4 (0.67)	0.77 (0.17-3.45)	0.736	-0.15 [-1.03 to 0.73]	9 (0.53)	19 (1.16)	0.46 (0.21-1.02)	0.057	-0.62 [-1.25 to 0.00]	0.552
Ischemic Stroke	3 (0.52)	3 (0.50)	1.03 (0.21-5.10)	0.971	0.01 [-0.80 to 0.83]	8 (0.47)	15 (0.91)	0.52 (0.22-1.23)	0.138	-0.44 [-1.00 to 0.13]	0.461
hemorrhagic Stroke	0 (0.00)	1 (0.17)	0.34 (0.01-8.33)	1.000	-0.17 [-0.49 to 0.16]	1 (0.06)	4 (0.25)	0.24 (0.03-2.19)	0.208	-0.18 [-0.45 to 0.08]	1.000
TIA	1 (0.18)	1 (0.17)	1.03 (0.06-16.45)	0.984	0.01 [-0.47 to 0.48]	4 (0.24)	8 (0.49)	0.49 (0.15-1.62)	0.242	-0.25 [-0.66 to 0.17]	0.628
Myocardial infarction	23 (3.97)	19 (3.17)	1.25 (0.68-2.30)	0.471	0.80 [-1.32 to 2.92]	37 (2.21)	30 (1.83)	1.21 (0.75-1.96)	0.436	0.38 [-0.58 to 1.34]	0.935
Definite or Probable Stent Thrombosis	4 (0.69)	6 (1.00)	0.69 (0.19-2.44)	0.562	-0.31 [-1.35 to 0.73]	10 (0.60)	3 (0.18)	3.27 (0.90-11.89)	0.072	0.41 [-0.01 to 0.84]	0.091
Definite Stent Thrombosis	4 (0.69)	4 (0.67)	1.03 (0.26-4.12)	0.965	0.02 [-0.92 to 0.96]	7 (0.42)	3 (0.18)	2.29 (0.59-8.85)	0.230	0.24 [-0.14 to 0.61]	0.419
Probable Stent Thrombosis	0 (0.00)	2 (0.33)	0.21 (0.01-4.36)	0.500	-0.33 [-0.79 to 0.13]	3 (0.18)	0 (0.00)	6.87 (0.36-132.90)	0.250	0.18 [-0.02 to 0.38]	1.000

## Bleeding BARC classification

Type 1	19 (3.28)	32 (5.34)	0.61 (0.34-1.07)	0.083	-2.06 [-4.37 to 0.25]	46 (2.73)	77 (4.65)	0.58 (0.40-0.83)	0.003	-1.93 [-3.21 to -0.65]	0.891
Type 2	26 (4.49)	42 (7.00)	0.63 (0.38-1.02)	0.061	-2.51 [-5.16 to 0.14]	76 (4.52)	110 (6.67)	0.67 (0.50-0.90)	0.007	-2.16 [-3.72 to -0.59]	0.824
Type 3	11 (1.90)	16 (2.67)	0.70 (0.33-1.52)	0.369	-0.77 [-2.47 to 0.93]	42 (2.50)	43 (2.61)	0.95 (0.62-1.46)	0.830	-0.10 [-1.17 to 0.97]	0.494
Type 3a	9 (1.55)	10 (1.67)	0.92 (0.38-2.27)	0.861	-0.12 [-1.55 to 1.32]	17 (1.01)	20 (1.21)	0.83 (0.44-1.59)	0.576	-0.20 [-0.91 to 0.52]	0.854
Type 3b	2 (0.35)	4 (0.67)	0.52 (0.09-2.82)	0.444	-0.32 [-1.13 to 0.49]	19 (1.13)	16 (0.97)	1.16 (0.60-2.26)	0.657	0.16 [-0.53 to 0.86]	0.381
Type 3c	1 (0.17)	2 (0.34)	0.52 (0.05-5.68)	0.588	-0.16 [-0.74 to 0.42]	6 (0.36)	7 (0.42)	0.84 (0.28-2.50)	0.754	-0.07 [-0.49 to 0.36]	0.717
Type 4	0 (0.00)	0 (0.00)				0 (0.00)	0 (0.00)				
Type 5	0 (0.00)	2 (0.34)	0.21 (0.01-4.36)	0.500	-0.34 [-0.80 to 0.13]	2 (0.12)	6 (0.37)	0.33 (0.07-1.62)	0.170	-0.25 [-0.58 to 0.09]	
Type 5a	0 (0.00)	0 (0.00)				0 (0.00)	2 (0.12)	0.20 (0.01-4.16)	0.245	-0.12 [-0.29 to 0.05]	1.000
Type 5b	0 (0.00)	2 (0.34)	0.21 (0.01-4.36)	0.500	-0.34 [-0.80 to 0.13]	2 (0.12)	4 (0.24)	0.49 (0.09-2.67)	0.409	-0.12 [-0.42 to 0.17]	
Type 3 or 5	11 (1.90)	18 (3.00)	0.63 (0.30-1.32)	0.219	-1.10 [-2.86 to 0.66]	44 (2.62)	49 (2.97)	0.88 (0.58-1.32)	0.529	-0.34 [-1.46 to 0.78]	0.435

1

2 Hazard ratio (95% CI) from Cox's time-to-first event analyses in ITT population. Continuity corrected risk ratios (95% CI) in case of zero events with Fisher's exact test p-value. Interaction p-value  
3 testing for modifying effect of Complex PCI (yes or no) on the hazard ratio scale. Absolute risk differences are shown as percentage points.

4 †includes undetermined strokes.

5 NACE = Co-primary composite endpoint of all-cause death, myocardial infarction, stroke and bleeding BARC 3 or 5

6 MACCE = Co-primary composite endpoint of all-cause death, myocardial infarction, stroke

7 MCB = Co-primary composite endpoint of bleeding BARC 2, 3 or 5

8

9

10

1 **Table 3. Clinical endpoints at 11 months post-randomization with Complex PCI and/or Acute Coronary Syndrome**

	Complex PCI or ACS					Noncomplex PCI and no ACS					interaction p-value
	Abbreviated DAPT N =1433	Standard DAPT N =1403	Hazard ratio (95% CI)	p-value	Absolute risk difference [95% CI]	Abbreviated DAPT N = 862	Standard DAPT N = 881	Hazard ratio (95% CI)	p-value	Absolute risk difference [95% CI]	
Net Adverse Clinical Events (NACE)	117 (8.19)	121 (8.66)	0.94 (0.73-1.21)	0.622	-0.47 [-2.52 to 1.58]	55 (6.42)	61 (6.95)	0.92 (0.64-1.32)	0.655	-0.54 [-2.89 to 1.82]	0.935
Major Adverse Cardiac or Cerebral events (MACCE)	100 (7.00)	97 (6.95)	1.00 (0.76-1.33)	0.974	0.06 [-1.82 to 1.93]	38 (4.44)	41 (4.68)	0.95 (0.61-1.48)	0.816	-0.24 [-2.20 to 1.72]	0.833
Major or Clinically Relevant Nonmajor Bleeding (MCB)	86 (6.10)	117 (8.46)	0.70 (0.53-0.93)	0.013	-2.36 [-4.29 to -0.44]	62 (7.27)	94 (10.78)	0.66 (0.48-0.91)	0.012	-3.51 [-6.21 to -0.81]	0.781
Death	52 (3.64)	55 (3.94)	0.92 (0.63-1.35)	0.670	-0.30 [-1.71 to 1.11]	23 (2.69)	26 (2.97)	0.91 (0.52-1.59)	0.727	-0.28 [-1.84 to 1.28]	0.960
Cardiovascular death	24 (1.70)	27 (1.95)	0.87 (0.50-1.50)	0.609	-0.26 [-1.25 to 0.74]	13 (1.53)	17 (1.95)	0.78 (0.38-1.61)	0.505	-0.42 [-1.65 to 0.81]	0.827
Non-cardiovascular death	20 (1.42)	20 (1.45)	0.97 (0.52-1.81)	0.933	-0.03 [-0.92 to 0.85]	9 (1.06)	8 (0.92)	1.15 (0.44-2.98)	0.772	0.14 [-0.80 to 1.07]	0.772
Undetermined death	8 (0.57)	8 (0.58)	0.97 (0.37-2.59)	0.957	-0.02 [-0.58 to 0.55]	1 (0.12)	1 (0.11)	1.02 (0.06-16.38)	0.986	0.00 [-0.32 to 0.32]	0.974
Cardiovascular or Undetermined death	32 (2.25)	35 (2.52)	0.89 (0.55-1.44)	0.636	-0.27 [-1.40 to 0.86]	14 (1.64)	18 (2.06)	0.80 (0.40-1.60)	0.521	-0.42 [-1.69 to 0.85]	0.794
Cerebrovascular Accident	10 (0.72)	20 (1.46)	0.49 (0.23-1.04)	0.062	-0.74 [-1.52 to 0.03]	7 (0.82)	12 (1.38)	0.60 (0.23-1.51)	0.277	-0.56 [-1.54 to 0.43]	0.741
Stroke¶	8 (0.57)	13 (0.95)	0.60 (0.25-1.44)	0.254	-0.38 [-1.03 to 0.27]	4 (0.47)	10 (1.15)	0.41 (0.13-1.31)	0.131	-0.68 [-1.53 to 0.16]	0.607
ischemic stroke	7 (0.50)	10 (0.73)	0.68 (0.26-1.79)	0.436	-0.23 [-0.81 to 0.35]	4 (0.47)	8 (0.92)	0.51 (0.15-1.70)	0.274	-0.45 [-1.24 to 0.33]	0.714
hemorrhagic stroke	1 (0.07)	3 (0.22)	0.32 (0.03-3.12)	0.330	-0.15 [-0.43 to 0.14]	0 (0.00)	2 (0.23)	0.20 (0.01-4.16)	0.500	-0.23 [-0.55 to 0.09]	
TIA	2 (0.15)	7 (0.51)	0.28 (0.06-1.34)	0.110	-0.37 [-0.80 to 0.06]	3 (0.36)	2 (0.23)	1.53 (0.26-9.18)	0.639	0.13 [-0.38 to 0.64]	0.160
Myocardial infarction	47 (3.34)	41 (2.99)	1.12 (0.74-1.70)	0.601	0.36 [-0.94 to 1.66]	13 (1.53)	8 (0.92)	1.67 (0.69-4.02)	0.256	0.61 [-0.43 to 1.66]	0.422
Definite or Probable Stent Thrombosis	12 (0.85)	8 (0.58)	1.47 (0.60-3.58)	0.403	0.27 [-0.36 to 0.90]	2 (0.24)	1 (0.11)	2.04 (0.19-22.54)	0.559	0.12 [-0.27 to 0.52]	0.798
Definite Stent Thrombosis	9 (0.64)	6 (0.44)	1.46 (0.52-4.11)	0.469	0.20 [-0.34 to 0.75]	2 (0.24)	1 (0.11)	2.04 (0.19-22.54)	0.559	0.12 [-0.27 to 0.52]	0.802

Probable Stent Thrombosis	3 (0.21)	2 (0.15)	1.46 (0.24-8.76)	0.677	0.07 [-0.25 to 0.38]	0 (0.00)	0 (0.00)				
Bleeding BARC classification											
Type 1	40 (2.83)	72 (5.22)	0.53 (0.36-0.79)	0.002	-2.38 [-3.84 to -0.93]	25 (2.93)	37 (4.24)	0.69 (0.41-1.14)	0.146	-1.31 [-3.06 to 0.44]	0.447
Type 2	59 (4.19)	84 (6.10)	0.67 (0.48-0.94)	0.020	-1.91 [-3.55 to -0.26]	43 (5.05)	68 (7.81)	0.64 (0.44-0.93)	0.021	-2.76 [-5.07 to -0.45]	0.825
Type 3	30 (2.13)	34 (2.46)	0.86 (0.52-1.40)	0.535	-0.33 [-1.44 to 0.78]	23 (2.71)	25 (2.87)	0.94 (0.53-1.65)	0.824	-0.16 [-1.72 to 1.40]	0.811
Type 3a	16 (1.14)	23 (1.67)	0.68 (0.36-1.28)	0.228	-0.53 [-1.40 to 0.34]	10 (1.18)	7 (0.80)	1.46 (0.56-3.84)	0.440	0.38 [-0.56 to 1.32]	0.190
Type 3b	12 (0.85)	8 (0.58)	1.46 (0.60-3.58)	0.406	0.27 [-0.35 to 0.90]	9 (1.06)	12 (1.38)	0.77 (0.32-1.82)	0.544	-0.32 [-1.36 to 0.72]	0.308
Type 3c	3 (0.21)	3 (0.22)	0.98 (0.20-4.83)	0.975	0.00 [-0.35 to 0.34]	4 (0.47)	6 (0.69)	0.68 (0.19-2.42)	0.553	-0.22 [-0.94 to 0.50]	0.731
Type 4	0 (0.00)	0 (0.00)				0 (0.00)	0 (0.00)				
Type 5	2 (0.14)	5 (0.36)	0.39 (0.08-2.01)	0.260	-0.22 [ -0.60 to 0.16]	0 (0.00)	3 (0.35)	0.15 (0.01-2.90)	0.250	-0.35 [-0.74 to 0.05]	
Type 5a	0 (0.00)	1 (0.07)	0.33 (0.01-8.09)	0.495	-0.07 [-0.21 to 0.07]	0 (0.00)	1 (0.12)	0.34 (0.01-8.33)	1.000	-0.12 [-0.35 to 0.11]	
Type 5b	2 (0.14)	4 (0.29)	0.49 (0.09-2.65)	0.405	-0.15 [-0.50 to 0.20]	0 (0.00)	2 (0.23)	0.20 (0.01-4.16)	0.500	-0.23 [-0.55 to 0.09]	
Type 3 or 5	32 (2.27)	39 (2.82)	0.80 (0.50-1.27)	0.339	-0.55 [-1.72 to 0.62]	23 (2.71)	28 (3.22)	0.84 (0.48-1.45)	0.527	-0.51 [-2.11 to 1.10]	0.890

1 Hazard ratio (95% CI) from Cox's time-to-first event analyses in ITT population. Continuity corrected risk ratios (95% CI) in case of zero events with Fisher's exact test p-value. Interaction p-value  
2 testing for modifying effect of Complex PCI or ACS vs none of these on the hazard ratio scale. Absolute risk differences are shown as percentage points.

3 †includes undetermined strokes.

4 NACE = Co-primary composite endpoint of all-cause death, myocardial infarction, stroke and bleeding BARC 3 or 5

5 MACCE = Co-primary composite endpoint of all-cause death, myocardial infarction, stroke

6 MCB = Co-primary composite endpoint of bleeding BARC 2, 3 or 5

7 ACS = STEMI, NSTEMI and Unstable angina.



1 **Table 4. Clinical endpoints at 11 months post-randomization with Acute Coronary Syndrome**


	Complex PCI				Noncomplex PCI				interaction p-value
	Abbreviated DAPT	Standard DAPT	Hazard ratio (95% CI)	p-value	Abbreviated DAPT	Standard DAPT	Hazard ratio (95% CI)	p-value	
	N = 283	N = 288			N = 845	N = 795			
Net Adverse Clinical Events (NACE)	28 (9.89)	28 (9.77)	1.00 (0.59-1.69)	0.998	68 (8.08)	72 (9.11)	0.88 (0.63-1.23)	0.450	0.683
Major Adverse Cardiac or Cerebral events (MACCE)	25 (8.83)	23 (8.02)	1.09 (0.62-1.93)	0.757	57 (6.77)	61 (7.72)	0.87 (0.61-1.25)	0.457	0.508
Major or Clinically Relevant Nonmajor Bleeding (MCB)	18 (6.46)	30 (10.68)	0.58 (0.33-1.05)	0.071	51 (6.14)	62 (7.93)	0.76 (0.52-1.10)	0.146	0.464
Death	12 (4.24)	12 (4.18)	1.00 (0.45-2.23)	0.994	33 (3.92)	37 (4.68)	0.83 (0.52-1.33)	0.446	0.695
Cardiovascular death	6 (2.15)	8 (2.82)	0.75 (0.26-2.17)	0.598	15 (1.80)	17 (2.18)	0.83 (0.41-1.65)	0.587	0.888
Non-cardiovascular death	4 (1.43)	4 (1.41)	1.00 (0.25-4.01)	0.996	14 (1.69)	13 (1.67)	1.01 (0.47-2.14)	0.989	0.997
Undetermined death	2 (0.72)	0 (0.00)	5.09 (0.25-105.55)	0.245	4 (0.48)	7 (0.91)	0.53 (0.16-1.82)	0.317	
Cardiovascular or Undetermined death	8 (2.85)	8 (2.82)	1.00 (0.38-2.67)	0.996	19 (2.27)	24 (3.06)	0.74 (0.41-1.35)	0.327	0.603
Cerebrovascular Accident	1 (0.37)	3 (1.08)	0.33 (0.03-3.20)	0.341	6 (0.73)	15 (1.94)	0.37 (0.14-0.96)	0.040	0.931
Stroke¶	0 (0.00)	2 (0.72)	0.20 (0.01-4.15)	0.499	5 (0.61)	9 (1.16)	0.52 (0.17-1.55)	0.239	
ischemic Stroke	0 (0.00)	1 (0.36)	0.34 (0.01-8.31)	1.000	4 (0.48)	7 (0.90)	0.53 (0.16-1.82)	0.316	
hemorrhagic Stroke	0 (0.00)	1 (0.36)	0.34 (0.01-8.31)	1.000	1 (0.12)	2 (0.26)	0.47 (0.04-5.14)	0.533	1.000
TIA	1 (0.37)	1 (0.36)	1.00 (0.06-15.93)	0.998	1 (0.12)	6 (0.78)	0.16 (0.02-1.29)	0.084	0.295
Myocardial infarction	15 (5.39)	12 (4.27)	1.26 (0.59-2.69)	0.552	24 (2.90)	22 (2.85)	1.02 (0.57-1.82)	0.946	0.667
Definite or Probable Stent Thrombosis	3 (1.08)	5 (1.79)	0.60 (0.14-2.51)	0.485	8 (0.97)	2 (0.26)	3.75 (0.80-17.67)	0.094	0.089
Definite Stent Thrombosis	3 (1.08)	3 (1.08)	1.00 (0.20-4.95)	0.999	5 (0.61)	2 (0.26)	2.34 (0.45-12.08)	0.309	0.467
Probable Stent Thrombosis	0 (0.00)	2 (0.71)	0.20 (0.01-4.15)	0.499	3 (0.36)	0 (0.00)	6.59 (0.34-127.38)	0.250	1.000
Bleeding BARC classification									

Type 1	9 (3.25)	16 (5.68)	0.56 (0.25-1.26)	0.159	21 (2.52)	40 (5.12)	0.49 (0.29-0.82)	0.007	0.773
Type 2	13 (4.69)	22 (7.88)	0.58 (0.29-1.15)	0.117	33 (3.98)	42 (5.40)	0.73 (0.46-1.15)	0.170	0.594
Type 3	6 (2.15)	8 (2.85)	0.75 (0.26-2.16)	0.592	19 (2.29)	18 (2.30)	0.99 (0.52-1.88)	0.964	0.665
Type 3a	5 (1.79)	5 (1.79)	1.00 (0.29-3.46)	0.999	7 (0.84)	13 (1.67)	0.50 (0.20-1.26)	0.142	0.379
Type 3b	1 (0.36)	2 (0.70)	0.50 (0.05-5.56)	0.576	10 (1.21)	4 (0.51)	2.34 (0.73-7.46)	0.151	0.257
Type 3c	0 (0.00)	1 (0.37)	0.34 (0.01-8.31)	1.000	2 (0.24)	1 (0.13)	1.87 (0.17-20.67)	0.608	
Type 4	0 (0.00)	0 (0.00)			0 (0.00)	0 (0.00)			
Type 5	0 (0.00)	2 (0.72)	0.20 (0.01-4.15)	0.499	2 (0.25)	3 (0.39)	0.62 (0.10-3.73)	0.604	1.000
Type 5a	0 (0.00)	0 (0.00)			0 (0.00)	1 (0.13)	0.31 (0.01-7.60)	0.485	1.000
Type 5b	0 (0.00)	2 (0.72)	0.20 (0.01-4.15)	0.499	2 (0.25)	2 (0.26)	0.93 (0.13-6.61)	0.944	
Type 3 or 5	6 (2.15)	10 (3.56)	0.60 (0.22-1.65)	0.321	21 (2.54)	21 (2.69)	0.93 (0.51-1.71)	0.823	0.461

1 Hazard ratio (95% CI) from Cox's time-to-first event analyses in ITT population. Continuity corrected risk ratios (95% CI) in case of zero events with Fisher's exact test p-value. Interaction p-value  
2 testing for modifying effect of Complex PCI (yes or no) on the hazard ratio scale.  
3 ††includes undetermined Strokes.  
4 NACE = Co-primary composite endpoint of all-cause death, myocardial infarction, stroke and bleeding BARC 3 or 5  
5 MACCE = Co-primary composite endpoint of all-cause death, myocardial infarction, stroke  
6 MCB = Co-primary composite endpoint of bleeding BARC 2, 3 or 5  
7 ACS = STEMI, NSTEMI and Unstable angina.

1 **Figure 1: antiplatelet regimens**


2 **A: antiplatelet regimens in complex PCI patients**



3


4

1 **B:** antiplatelet regimens in noncomplex PCI patients



2  
3


1 **Figure 2: Clinical endpoints stratified by complexity of percutaneous coronary intervention**



2


3

1 **Figure 3**



	No. at risk	0	30	60	90	120	150	180	210	240	270	300	335
Standard DAPT (Complex)	608	590	580	575	569	567	561	555	551	544	538	535	
Abbreviated DAPT (Complex)	588	582	578	577	573	565	563	559	554	548	543	536	
Standard DAPT (Noncomplex)	1676	1630	1606	1591	1578	1555	1533	1522	1509	1491	1477	1464	
Abbreviated DAPT (Noncomplex)	1707	1687	1671	1646	1629	1608	1598	1591	1576	1569	1559	1542	

2

1 **Figure 4: Clinical endpoints in acute coronary syndrome patients stratified by complexity of percutaneous coronary intervention**

2

1

2 No permission is needed for the figures in the main manuscript or supplementary appendix because all are original.

3

4

## 5 **Disclosure**

6 Marco Valgimigli received an institutional grant from Terumo and consulting fees from Astra Zeneca, Terumo, Alvimedica/CID, Abbott Vascular,  
7 Daiichi Sankyo, Bayer, CoreFLOW, DORSIA Pharmaceuticals LTD, Vifor, Bristol Myers Squibb SA, Biotronik, Boston scientific, Medtronic,  
8 Vesalio, Novartis, Chiesi, PhaseBio, ECRI. Pieter C. Smits received institutional grants from Microport, SMT, Daichy Sankyo and Abbott  
9 Vascular; consulting fees from Cavis and Abbott Vascular; honoraria from Abiomed, Terumo and Abbott Vascular; participated on advisory  
10 board of Terumo, Abbott Vascular and SMI. Bela Merkely received grants from Medtronic and Boston Scientific; Speaker fee from Biotronik,  
11 Abbott, Astra Zeneca, Boehringer Ingelheim and Novartis. Thomas Cuisset received consulting fees from Medtronic, Abbott vascular, Terumo  
12 and Boston Scientific; honoraria from Medtronic, Abbott vascular, Terumo and Boston Scientific. Fazila Tun Nesa Malik received consulting fees  
13 from Terumo. Krzysztof Reczuch received honoraria from Boston Scientific, Terumo and Astra Zeneca. Pascal Vranckx received consulting  
14 fees from Daiichi Sankyo, Novartis, CSL Behring and Bayer AG; honoraria from Daiichi Sankyo and Servier; participated on advisory board for  
15 Daiichi Sankyo. All other authors declared no conflict of interest.

## 16 **ROLE OF THE FUNDING SOURCE**

17 The study was sponsored by the European Cardiovascular Research Institute (ECRI), a non-profit organisation, and received grant support from Terumo. The  
18 sponsor and funder had no role in the study design, data collection, data monitoring, analysis, interpretation, or writing of the report.